Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Why CogState, Jumbo, Magellan, and St Barbara shares are rising today
2 ASX All Ords stocks rocketing over 7% on strong results
Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking
3 ASX All Ord shares being hammered on earnings today
Why A2 Milk, Altium, Cogstate, and Ingenia shares are sinking today
Why CogState, Downer, Temple & Webster, and Woodside shares are dropping
These 2 small-cap ASX shares have soared, but a fund manager still tips them as buys
2 ASX healthcare shares to buy that you've not heard of: expert
Here's how ASX tech shares fared in September
These were the 5 best-performing ASX All Ords shares in September
Why Cogstate, Global Lithium, Premier, and Woodside shares are charging higher
No, Cogstate does not pay dividends at this stage.
Cogstate Ltd listed on the ASX on 13 February 2004.
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Cogstate Ltd (ASX: CGS) is a neuroscience technology company specialising in brain health assessments. The principal activity of the company is the sale of technology and services to measure cognition.
The company provides licensed digital tests for health professionals and medical researchers. Its services include scientific consultancy, project management, data management, statistical analysis, and reporting. Cogstate generates the bulk of its revenue from its clinical trials segment.
Cogstate's technology has been used in more than 2,000 scientific and clinical trial studies. These include fields such as Alzheimer's, depression, and bipolar disorder research as well as studies investigating cognitive impairment in athletes as a result of concussive injuries.
|01 Dec 2023||$1.44||$0.02||1.41%||204,121||$1.43||$1.44||$1.36|
|30 Nov 2023||$1.42||$0.01||0.71%||156,584||$1.42||$1.44||$1.38|
|29 Nov 2023||$1.41||$-0.10||-6.62%||305,883||$1.51||$1.51||$1.40|
|28 Nov 2023||$1.51||$0.02||1.34%||167,657||$1.49||$1.51||$1.47|
|27 Nov 2023||$1.49||$-0.04||-2.61%||203,147||$1.52||$1.52||$1.47|
|24 Nov 2023||$1.53||$0.00||0.00%||132,445||$1.53||$1.56||$1.53|
|23 Nov 2023||$1.54||$0.03||1.99%||189,339||$1.51||$1.56||$1.49|
|22 Nov 2023||$1.51||$0.04||2.74%||320,152||$1.46||$1.51||$1.46|
|21 Nov 2023||$1.46||$0.00||0.00%||130,895||$1.46||$1.48||$1.45|
|20 Nov 2023||$1.46||$0.00||0.00%||339,377||$1.46||$1.49||$1.44|
|17 Nov 2023||$1.46||$0.01||0.69%||87,677||$1.46||$1.46||$1.44|
|16 Nov 2023||$1.45||$-0.04||-2.68%||334,824||$1.50||$1.50||$1.44|
|15 Nov 2023||$1.49||$-0.01||-0.66%||447,914||$1.49||$1.52||$1.47|
|14 Nov 2023||$1.51||$-0.06||-3.85%||125,288||$1.53||$1.53||$1.47|
|13 Nov 2023||$1.56||$0.08||5.39%||104,409||$1.49||$1.56||$1.48|
|10 Nov 2023||$1.49||$0.00||0.00%||362,667||$1.50||$1.53||$1.48|
|09 Nov 2023||$1.49||$-0.07||-4.49%||526,895||$1.50||$1.53||$1.46|
|08 Nov 2023||$1.56||$0.04||2.63%||67,870||$1.53||$1.59||$1.53|
|07 Nov 2023||$1.52||$0.02||1.33%||236,501||$1.53||$1.53||$1.51|
|06 Nov 2023||$1.51||$0.04||2.73%||314,850||$1.50||$1.52||$1.49|
|03 Nov 2023||$1.47||$-0.04||-2.66%||668,467||$1.52||$1.52||$1.46|
|02 Nov 2023||$1.51||$-0.02||-1.32%||9,919||$1.52||$1.52||$1.50|
|16 May 2023||Richard Mohs||Buy||12,000||$20,640||
|07 Mar 2023||Martyn Myer||Buy||50,000||$76,734||
On-market trade. average price
|07 Mar 2023||Bradley O'Connor||Buy||32,500||$50,205||
|07 Mar 2023||Bradley O'Connor||Buy||32,500||$50,169||
|Mr Martyn Kenneth Myer||Non-Executive ChairmanNon-Executive Director||Oct 1999||
Mr Myer is Chair of the Doherty Institute at the University of Melbourne and the boards of the Australian Chamber Orchestra and Watertrust Australia Limited. He previously served as Deputy Chancellor of the Council of the University of Melbourne, President of The Myer Foundation, one of two principle Myer Family philanthropic funds, President of the Howard Florey Institute of Experimental Physiology and Medicine and was a director of The Florey Institute of Neuroscience and Mental Health, where he participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. He is also a member of Risk and Compliance Committee.
|Mr Bradley O'Connor||Chief Executive OfficerManaging Director||Nov 2005||
Mr O'Connor has responsibility for Cogstate's overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business. Prior to taking the position of CEO at Cogstate in 2005, Mr O'Connor joined Cogstate as Chief Financial Officer and Company Secretary in 2004. Prior to that, Mr O'Connor held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers.
|Ms Ingrid Anne Player||Non-Executive Director||Aug 2019||
Ms Player brings healthcare sector experience and commercial expertise to the Board of Cogstate. She has held senior executive roles with Healthscope Ltd, a private healthcare provider in Australia, including the former positions of Group Executive Legal, Governance and Sustainability, and General Counsel and Company Secretary from 2005 until 2019. Ms Player also has international commercial and regulatory experience that spans different markets and industries, which she gained in private legal practice in Australia and in The Netherlands. She is Chair of Risk and Compliance Committee.
|Mr Richard van den Broek||Non-Executive Director||Aug 2010||
Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. Prior to his time as an investor in the healthcare industry Mr van den Broek had a ten-year career as a biotech analyst, starting at Oppenheimer and Co., then Merrill Lynch, and finally at Hambrecht and Quist.
|Dr Richard Mohs||Non-Executive Director||Jan 2017||
Dr Mohs is currently Chief Scientific Officer for the Global Alzheimer's Platform (GAP) Foundation, a non-profit devoted to enhancing the speed and quality of Alzheimer's disease research. Richard also serves as a consultant to academic institutions, foundations, and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer's Drug Discovery Foundation. Dr Mohs retired from Eli Lilly in 2015, where he held leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer's Drug Development Team. Before joining Eli Lilly, Dr Mohs spent 23 years with the Mount Sinai School of Medicine where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Centre. He is also a member of the Risk and Compliance Committee.
|Ms Kim Wenn||Non-Executive Director||Nov 2020||
Ms Wenn brings technology experience and commercial expertise to the Board of Cogstate, with over 30 years of experience in innovation roles. Until July 2018, Kim held the role of Chief Information Officer at Tabcorp Holdings, an ASX50 listed company where Kim led a team of 1,200 technology experts to drive strategic direction through digital transformation. Kim's experience includes, among other things, business strategy, governance, and change management with a focus on digital disruption. She is also a member of Risk and Compliance Committee.
|Mr David James Franks||Company Secretary||Feb 2021||
|Ms Kristi Geddes||Joint Company Secretary||Apr 2023||
|Darren Watson||Chief Financial Officer||
|Paul Maruff||Chief Innovation Officer||
|Chris Edgar||Chief Science Officer||
|David James Franks||Company Secretary||
|Rachel Colite||Executive Vice President Clinical Trials||
|Kristi Geddes||Joint Company Secretary||
|Citicorp Nominees Pty Limited||26,467,388||15.30%|
|Dagmar Dolby Fund||25,732,802||14.90%|
|HSBC Custody Nominees||18,733,273||10.80%|
|National Nominees Limited||18,423,798||10.60%|
|Myer and Myer Pty Ltd||14,424,569||8.30%|
|Anacacia Pty Limited||8,276,801||4.80%|
|Mpyer Investments Pty Ltd||6,061,872||3.50%|
|BNP Paribas Nominees Pty Ltd||5,796,914||3.30%|
|Mr Bradley John O'Connor||3,488,429||2.00%|
|BNP Paribas Noms Pty Ltd||2,919,932||1.80%|
|HSBC Custody Nominees i||2,785,398||1.60%|
|Myer and Myer Pty Ltd i||2,313,000||1.30%|
|J P Morgan Nominees Australia||1,750,592||1.00%|
|Mr Alistair David Strong||1,320,000||0.80%|
|Mutual Trust Pty Ltd||1,223,806||0.70%|
|Beta Gamma Pty Ltd||1,220,000||0.70%|
|BNP Paribas Noms(Nz) Ltd<Drp>||1,209,851||0.70%|
|BNP Paribas Nominees Pty Ltd i||1,169,901||0.70%|
|Mr David Alexander Simpson||1,000,689||0.60%|
|HSBC Custody Nominees ii||924,111||0.50%|